Group 1 - The core viewpoint of the article highlights the decline of the artemisinin concept sector, which fell by 0.82%, ranking among the top declines in the concept sector [1][2] - Within the artemisinin concept sector, major companies such as Rundu Co., Zhejiang Medicine, and Kunming Pharmaceutical experienced significant declines, while only two stocks, Delong Huineng and Baiyunshan, saw increases of 1.06% and 0.37% respectively [1][2] - The article provides a detailed overview of the capital flow, indicating a net outflow of 58 million yuan from the artemisinin concept sector, with Rundu Co. leading the outflow at 43.43 million yuan [2] Group 2 - The article lists the top-performing concept sectors, with the military equipment restructuring concept leading with a gain of 3.92%, while the artemisinin concept was among the worst performers [2] - A table is provided showing the capital flow for various companies within the artemisinin concept, detailing their respective price changes and turnover rates, with Rundu Co. showing a significant outflow [2]

Group 1 - The company’s wholly-owned subsidiary, Run Du Pharmaceutical (Jingmen) Co., Ltd., has received the veterinary product approval number for "Florfenicol" from the Ministry of Agriculture and Rural Affairs [1][2] - The product is a commonly used veterinary antibiotic with a broad antibacterial spectrum, suitable for large-scale farming operations, primarily used for the prevention and treatment of bacterial diseases in cattle, poultry, pigs, and fish [1][2] - The approval number is valid from April 25, 2025, to April 24, 2030, indicating a significant timeline for market entry [1] Group 2 - The company has obtained the "Veterinary Production License" and "Veterinary GMP Certificate" for the product, indicating readiness for market sales [2] - The approval of Florfenicol will enrich the company’s product line and structure, enhancing its strategic layout in the veterinary medicine sector and improving market competitiveness [3]

Group 1 - Shengyi Electronics plans to repurchase shares with a total amount between 50 million and 100 million yuan, at a price not exceeding 43.02 yuan per share, for employee stock ownership plans [1] - Guoyao Modern's subsidiary has passed the consistency evaluation for the quality and efficacy of a generic drug, which is used for treating severe infections [1] - Tianhe Magnetic Materials' subsidiaries have obtained project filing notices for high-performance rare earth permanent magnet projects, with total investments of 100 million yuan and 50 million yuan respectively [1][2] Group 2 - Dream Lily intends to repurchase shares with an amount between 85 million and 170 million yuan, at a price not exceeding 10.90 yuan per share, supported by a loan commitment of up to 150 million yuan [3] - Weifu High-Tech has received a loan commitment of up to 135 million yuan from a financial institution for share repurchase [3] Group 3 - Lu'an Environmental Energy reported a coal sales volume of 4.51 million tons in April, a year-on-year increase of 17.75% [5] - *ST Tianshan reported a significant decline in livestock sales and revenue, with a revenue of 70,500 yuan in April, down 95.68% year-on-year [7] Group 4 - Feirongda announced a cash dividend of 0.38 yuan per 10 shares, with a total distribution of 21.9 million yuan [8] - Zhejiang Rongtai's shareholders and executives plan to reduce their holdings by up to 1.93% of the company's shares [9] Group 5 - Changhua Group's subsidiary won the land use rights for an industrial site in Ningbo for 27.05 million yuan, intended for manufacturing and related business [11] - Zejing Pharmaceutical's new drug application for a treatment for severe alopecia has been accepted by the regulatory authority [13][14] Group 6 - Hainan Mining plans to distribute a cash dividend of 0.8 yuan per 10 shares, totaling 1.59 billion yuan [15] - China Jushi plans to distribute a cash dividend of 0.24 yuan per share, totaling 9.61 billion yuan [16] Group 7 - Zhengzhong Design's subsidiary has obtained a utility model patent for an acrylic signage guide [18] - Rundu Co., Ltd. received approval for a veterinary drug product, which is intended for treating bacterial diseases in livestock [20] Group 8 - Emei Mountain A announced the resignation of its general manager due to work reasons [22] - Tonghua Dongbao's insulin injection has received a registration certificate in Nicaragua, allowing for sales in that market [23] Group 9 - Dizu Fashion's subsidiary has completed the registration of a private equity investment fund [24] - Ningbo Gaofa plans to increase capital by 60 million yuan in its subsidiary for operational needs [26] Group 10 - Haichuan Intelligent has obtained two utility model patents for material handling devices [27] - Newland's subsidiary signed a deep cooperation agreement with Alibaba Cloud for AI model applications [29] Group 11 - Rui Neng Technology's controlling shareholder plans to reduce its stake by up to 2.89% [30] - Guomai Culture intends to repurchase shares between 50 million and 100 million yuan for capital reduction [31] Group 12 - Shaanxi Construction won major construction projects totaling 7.88 billion yuan in April [32] - Hanyu Pharmaceutical signed a joint development agreement for a new peptide drug with a partner [34] Group 13 - Yunnan Copper is planning to acquire a 40% stake in Liangshan Mining, leading to a stock suspension [35] - Haizheng Pharmaceutical plans to repurchase shares between 50 million and 100 million yuan for employee stock ownership [36] Group 14 - Tianqiao Hoisting's controlling shareholder plans to increase its stake by 75 million to 150 million yuan [37] - Tiandi Online's controlling shareholder is transferring shares to introduce a strategic investor [38] Group 15 - Hongchang Technology plans to invest 15 million yuan in a joint venture with a partner [39] - Rabbit Baby's subsidiary is preparing for an IPO in Hong Kong [41] Group 16 - Wol Nuclear Materials is planning to issue H-shares for listing in Hong Kong [42] - Tangyuan Electric plans to raise up to 864 million yuan through a private placement for various projects [43] Group 17 - Tongrun Equipment's major shareholders plan to reduce their holdings by up to 2% [44] - Linzhou Heavy Machinery plans to raise up to 600 million yuan through a private placement [46] Group 18 - China Merchants Securities announced the resignation of its vice president [47] - Shangsheng Electronics plans to issue convertible bonds to raise up to 330 million yuan for various projects [48] Group 19 - Longda Co., Ltd.'s major shareholder plans to reduce its stake by up to 1% [49] - China Medical plans to acquire 100% of Jinsui Technology for 302 million yuan [50] Group 20 - Silek has signed a strategic cooperation agreement with a battery manufacturer [51] - Boyun New Materials' major shareholder plans to reduce its stake by up to 3% [53]

证券代码：002923 证券简称：润都股份 公告编号：2025-021 珠海润都制药股份有限公司 关于公司全资子公司获得兽药产品批准文号批件的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，珠海润都制药股份有限公司（以下简称"公司"）全资子公司润都制 药（荆门）有限公司（以下简称"润都荆门公司"）收到国家农业农村部审批签 发的"氟苯尼考"（非无菌原料药）的兽药产品批准文号批件。现将有关情况公 告如下： 一、批件信息 通用名称：氟苯尼考（以下简称"本品"） 企业名称：润都制药（荆门）有限公司 兽药产品批准文号：兽药原字170782108 生产地址：荆门市掇刀区荆门化工循环产业园荆东大道325、327、329号 有效期：2025年04月25日至2030年04月24日 二、产品信息 润都荆门公司已取得本品的《兽药生产许可证》及《兽药GMP证书》，并已将 相关材料上报国家农业农村部，目前已取得本品的批准文号批件，具备上市销售 条件。 三、对公司的影响及风险提示 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安 全。此次润都荆门公司的氟苯尼 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 珠海润都制药股份有限公司（以下简称"公司"或"本公司"）近日收到国 家药品监督管理局签发的《药品注册证书》。现将有关情况公告如下： 一、药品基本情况 药品名称：单硝酸异山梨酯片（以下简称"本品"） 剂型：片剂 申请事项：药品注册(境内生产) 规格：20mg 证券代码：002923 证券简称：润都股份 公告编号：2025-020 珠海润都制药股份有限公司 关于单硝酸异山梨酯片获得药品注册证书的公告 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。 二、药品的适应症 本品适用于冠心病的长期治疗；心绞痛的预防；心肌梗死后持续心绞痛的治 疗；与洋地黄和/或利尿剂联合应用，治疗慢性充血性心力衰竭。 三、对公司的影响及风险提示 公司高度重视药品研发，并严格控制药品研发、制造及销售环节的质量及安 全。此次单硝酸异山梨酯片获得国家药监局的《药品注册证书》，进一步丰富了 注册分类：化学药品4类 受理号：CYHS23 ...

Core Viewpoint - The article highlights a trend of decreasing shareholder accounts in several companies, indicating a concentration of shares among fewer investors, with some companies experiencing a significant decline over multiple periods [1][2]. Group 1: Shareholder Account Trends - A total of 101 companies reported their latest shareholder account numbers as of May 10, with 14 companies showing a continuous decline for more than three periods, and some experiencing a drop for up to seven periods [1]. - Notable companies with prolonged declines include Kangxin New Materials, which has 44,113 shareholders, down 26.72% over seven periods, and Dingxin Communications, with 30,474 shareholders, down 21.81% over the same duration [1][2]. - Other companies with significant declines in shareholder accounts include Guotou Intelligent and Changcheng Securities, among others [1]. Group 2: Market Performance - Among the companies with decreasing shareholder accounts, only one has seen its stock price rise, while 13 have experienced declines, with HaiXiang Pharmaceutical showing a notable increase of 1.76% [1]. - In terms of relative performance against the Shanghai Composite Index, only one company outperformed the index, with HaiXiang Pharmaceutical achieving a relative return of 2.93% [1][2]. Group 3: Industry Distribution - The industries with the highest concentration of companies experiencing declining shareholder accounts include machinery equipment, pharmaceuticals, and communications, with three, two, and two companies respectively [2]. - The distribution of these companies shows that eight are listed on the main board and six on the ChiNext board [2]. Group 4: Detailed Company Data - A table lists companies with their latest shareholder accounts, percentage changes, consecutive decline periods, and stock performance, highlighting significant declines for companies like Naipu Mining (-5.40%), Rundu Co., Ltd. (-4.85%), and Aotexun (-1.90%) [2][3]. - Kangxin New Materials and Dingxin Communications are among those with the longest consecutive declines, with respective declines of 0.34% and 0.40% in the latest period [3].

Group 1 - The core viewpoint of the news indicates that the Artemisinin concept sector experienced a decline of 0.81%, ranking among the top declines in the concept sector [1] - Within the Artemisinin concept sector, major companies such as Kunming Pharmaceutical Group, New Harmony, and Rundu Co., Ltd. saw significant declines, while companies like Baihua Pharmaceutical, China Resources Sanjiu, and Zhejiang Medicine recorded gains of 1.21%, 0.75%, and 0.75% respectively [1] Group 2 - The financial data shows that the Artemisinin concept sector had a net outflow of 96 million yuan, with eight stocks experiencing net outflows, led by Kunming Pharmaceutical Group with a net outflow of 62.05 million yuan [2] - Other companies with notable net outflows include Rundu Co., Ltd. with 11.84 million yuan, Fosun Pharmaceutical with 9.02 million yuan, and Zhejiang Medicine with 6.48 million yuan [2] - Conversely, the stocks with the highest net inflows included Baihua Pharmaceutical and New Harmony, with net inflows of 6.07 million yuan and 1.19 million yuan respectively [2]

证券代码：002923 证券简称：润都股份 公告编号：2025-018 珠海润都制药股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 一、召开会议的基本情况 1、股东大会届次：2024 年年度股东大会 2、股东大会的召集人：本次股东大会由公司董事会召集，经公司第五届董 事会第十二次会议审议通过《关于召开 2024 年年度股东大会的议案》，同意召开 本次股东大会。 3、会议召开的合法、合规性：本次股东大会的召开符合有关法律、行政法 规、部门规章、规范性文件、深圳证券交易所业务规则和公司章程的相关规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 05 月 20 日（星期二）14:30 开始； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 05 月 20 日的交易时间，即上午 9:15-9:25，9:30-11:30 和 13:00- 15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 05 月 20 日上午 9 ...

证券代码：002923 证券简称：润都股份 公告编号：2025-011 珠海润都制药股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 珠海润都制药股份有限公司（以下简称"公司"）第五届监事会第十次会议 于 2025 年 04 月 28 日上午 11:30 以现场结合通讯表决的方式召开，会议通知以 电子邮件方式于 2025 年 04 月 18 日向各位监事发出。本次会议由监事会主席华 志军先生召集和主持。应出席会议监事 3 名，实际出席会议监事 3 名；其中，现 场出席监事 2 人，通讯表决监事 1 人（华志军先生以线上视频方式出席本次会 议）。会议召集及召开程序符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 二、监事会会议审议情况 1、审议通过了《2024 年度财务会计报告》。 公司聘请的中审众环会计师事务所（特殊普通合伙）对公司 2024 年的经营 情况进行了审计，并出具了标准无保留意见的《珠海润都制药股份有限公司 2024 年年度审计报告》（众环审字(2025)05005 ...